Ralliant (NYSE:RAL) CEO Sells $928,675.44 in Stock

Ralliant Corporation (NYSE:RAL) CEO Tamara Newcombe sold 12,936 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. This trade represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Price Performance

RAL stock opened at $64.12 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The firm has a market cap of $7.09 billion, a price-to-earnings ratio of -5.91, a PEG ratio of 2.47 and a beta of 1.60. The company’s fifty day simple moving average is $68.99 and its 200 day simple moving average is $55.86. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, analysts expect that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s payout ratio is presently -1.84%.

Analyst Ratings Changes

A number of equities analysts have issued reports on RAL shares. Citigroup increased their price target on Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Oppenheimer boosted their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Morgan Stanley increased their target price on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 23rd. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a report on Wednesday, May 27th. Finally, Evercore initiated coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RAL. Danske Bank A S bought a new stake in shares of Ralliant in the 4th quarter worth $25,000. Dunhill Financial LLC purchased a new position in Ralliant during the second quarter worth about $25,000. Allworth Financial LP grew its position in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant in the 3rd quarter worth about $26,000. Finally, BOKF NA purchased a new stake in Ralliant in the 3rd quarter valued at about $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.